Skip to main content

Search TrendsNew Ads Appearances Podcasts API

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

Optimizing Real-World Management of Early Alzheimer’s Disease: Maintenance Therapy and Long-Term Evidence

Sep 14, 2026 · 20 min · 7 segments

Please visit answersincme.com/TZA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James E. Galvin, MD, MPH. In this activity…

Please visit answersincme.com/TZA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James E. Galvin, MD, MPH. In this activity, an expert in Alzheimer’s disease (AD) discusses treatment of early AD with anti-amyloid therapies. Upon completion of this activity, participants should be better able to: Review the latest advances in anti-amyloid therapies for the treatment of early Alzheimer’s disease (AD; Assess the current evidence on anti-amyloid therapies, including maintenance strategies, for the treatment of early AD; and Outline strategies to integrate the latest advances in anti-amyloid therapies to practice to improve long-term outcomes for patients with early AD.

Please visit answersincme.com/TZA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James E. Galvin, MD, MPH. In this activity…

Speakers: James GalvinGuest

Show signals: SuitabilitySafeBiasNot politicalAudience≈165 followers

Spotify Apple Podcasts YouTube Website

Top entities: Lecanemab×6 James E Galvin×4 Food and Drug Administration×4 Donanemab×5 Eisai×2

CME Program Introduction0:00 – 0:58

N

NarratorNarrator

0:00

[outro music] Welcome.

N

NarratorNarrator

0:08

The following presentation from Answers in CME is part of an educational activity titled "Optimizing Real-World Management of Early Alzheimer's Disease: Maintenance Therapy and Long-Term Evidence." To access the full program and supporting materials and to claim your certificate, please visit the activity URL in the episode description.

N

NarratorNarrator

0:30

This activity is supported by an independent educational grant from Eisai.

N

NarratorNarrator

0:35

This is a unique CME program.

N

NarratorNarrator

0:38

We've conducted a survey with neurologists, nurse practitioners, and physician associates, including community clinicians and internal medicine specialists, to gather their feedback and questions about real-world treatment of early Alzheimer's disease with anti-amyloid therapies.

N

NarratorNarrator

0:54

Our faculty will now address the most commonly asked questions.

Read the full transcript.

Create an account to read the whole episode, search across every transcript, and follow the shows you care about.

Sign up Already have an account? Log in

LecanemabEntityMedication
96%6 mentions
James E GalvinPersonPhysician
88%4 mentions
Food and Drug AdministrationGovernment OrganizationFederal agency
79%4 mentions
DonanemabEntityDrug
71%5 mentions
EisaiCompanyPharmaceutical company
63%2 mentions
mild cognitive impairmentEntityDisease
54%3 mentions
Magnetic resonance imagingEntityMedical imaging
46%8 mentions
Intravenous therapyEntity
38%1 mention
Boca RatonCityCity in Florida
21%1 mention
FloridaAdministrative AreaUS state
21%1 mention
Leonard M. Miller School of MedicineEntityUniversity in Miami, Florida
21%1 mention
Alzheimer's Disease Neuroimaging InitiativeEvent
4%3 mentions

HealthcareHealth
Monitoring and SafetyHealth > Healthcare > Patient Management > Treatment Protocols
Lecanemab and Donanemab TrialsHealth > Healthcare > Clinical Trials > Efficacy Studies
Monoclonal AntibodiesHealth > Healthcare > Pharmacology > Drug Administration
NeurologyHealth > Healthcare
Alzheimer's DiseaseHealth > Healthcare > Neurology
Patient ManagementHealth > Healthcare
Efficacy StudiesHealth > Healthcare > Clinical Trials
Treatment ProtocolsHealth > Healthcare > Patient Management
Informed ConsentHealth > Healthcare > Patient Education
Drug AdministrationHealth > Healthcare > Pharmacology
Anti-Amyloid TherapiesHealth > Healthcare > Neurology > Alzheimer's Disease
Shared Decision-MakingHealth > Healthcare > Patient Education > Informed Consent
Clinical TrialsHealth > Healthcare
PharmacologyHealth > Healthcare
Patient EducationHealth > Healthcare
Health

CME Program Introduction0:00 – 0:58

N

NarratorNarrator

0:00

[outro music] Welcome.

N

NarratorNarrator

0:08

The following presentation from Answers in CME is part of an educational activity titled "Optimizing Real-World Management of Early Alzheimer's Disease: Maintenance Therapy and Long-Term Evidence." To access the full program and supporting materials and to claim your certificate, please visit the activity URL in the episode description.

N

NarratorNarrator

0:30

This activity is supported by an independent educational grant from Eisai.

N

NarratorNarrator

0:35

This is a unique CME program.

N

NarratorNarrator

0:38

We've conducted a survey with neurologists, nurse practitioners, and physician associates, including community clinicians and internal medicine specialists, to gather their feedback and questions about real-world treatment of early Alzheimer's disease with anti-amyloid therapies.

N

NarratorNarrator

0:54

Our faculty will now address the most commonly asked questions.